Table of contents
November 2005 - Volume 64 - suppl 4
Advances in targeted therapies VII
- Preface
- Consensus statement
- Novel aspects of cellular immunology
- Issues in clinical trial design
- Adverse events with biologics
- Joint damage
- Update on biologicals
- Psoriasis, psoriatic arthritis, ankylosing spondylitis, and other aspects
- TNF effects and therapeutic response
- Molecular basis of the immune response
- New targets I
- New targets II
- New targets III
- Epilogue
Preface
- Advances in targeted therapies VII (20 October, 2005)
Consensus statement
Novel aspects of cellular immunology
- Stimulation of autoimmunity by toll-like receptor ligands (20 October, 2005)
Issues in clinical trial design
- Biological drug use: US perspectives on indications and monitoring (20 October, 2005)
Adverse events with biologics
- The CORRONA database (20 October, 2005)
- The British Society for Rheumatology Biologics Register (20 October, 2005)
Joint damage
- What are the roles of metalloproteinases in cartilage and bone damage? (20 October, 2005)
- Are fibroblasts involved in joint destruction? (20 October, 2005)
Update on biologicals
- Update on rituximab (20 October, 2005)
- Alefacept for psoriasis and psoriatic arthritis (20 October, 2005)
Psoriasis, psoriatic arthritis, ankylosing spondylitis, and other aspects
- Health economics: implications for novel antirheumatic therapies (20 October, 2005)
TNF effects and therapeutic response
- What does tumour necrosis factor excess do to the immune system long term? (20 October, 2005)
Molecular basis of the immune response
- How does B cell depletion therapy work, and how can it be improved? (20 October, 2005)
New targets I
- IKKβ as a target for treatment of inflammation induced bone loss (20 October, 2005)
- Dendritic cells: potential triggers of autoimmunity and targets for therapy (20 October, 2005)
New targets II
New targets III
- Toll-like receptor 2 signalling and inflammation (20 October, 2005)